0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      MicroRNA regulation of liver cancer stem cells

      review-article

      Read this article at

      ScienceOpenPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          MicroRNAs (miRNAs), a class of emerging small non-coding RNAs, serve as vital players in modulating multiple biological processes via the post-transcriptional regulation of gene expression. Dysregulated expression of miRNAs in liver cancer is well documented, and the involvement of miRNAs in liver cancer initiation and progression has also been described. Cancer stem cells (CSCs) are a subset of cells known to be at the root of cancer recurrence and resistance to therapy. In this review, we highlight recent reports indicating that miRNAs participate in the regulation of liver cancer stem cells (LCSCs). The Wnt signaling pathway, TGF-beta signaling pathway, JAK/STAT signaling pathway and epithelial-mesenchymal transition (EMT) are all closely correlated with the miRNA modulation of LCSCs. In addition, several miRNAs have been demonstrated to be involved in the regulation of LCSCs in response to therapy sensitivity. Targeting LCSCs by regulating the expression of these miRNAs represents a potential therapeutic strategy for treating cancer drug resistance, metastasis and recurrence in the near future.

          Related collections

          Author and article information

          Journal
          Am J Cancer Res
          Am J Cancer Res
          ajcr
          American Journal of Cancer Research
          e-Century Publishing Corporation
          2156-6976
          2018
          01 July 2018
          : 8
          : 7
          : 1126-1141
          Affiliations
          [1 ] Program of Innovative Cancer Therapeutics, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, College of Medicine, Zhejiang University, Key Laboratory of Organ Transplantation Hangzhou 310003, Zhejiang Province, China
          [2 ] Key Laboratory of Organ Transplantation Hangzhou 310003, Zhejiang Province, China
          [3 ] Key Laboratory of Combined Multi-organ Transplantation, Ministry of Public Health Hangzhou 310000, China
          [4 ] Department of Intensive Care Unit, Changxing People’s Hospital of Zhejiang Huzhou 313100, Zhejiang Province, China
          [5 ] Department of Anesthesiology, International Hospital of Zhejiang University, Shulan (Hangzhou) Hospital Hangzhou 310003, Zhejiang Province, China
          [6 ] Department of Thyroid and Breast Surgery, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College Hangzhou 310000, Zhejiang Province, China
          [7 ] Department of Pathology and Laboratory Medicine, Medical University of South Carolina Charleston, SC 29425, USA
          Author notes
          Address correspondence to: Weimin Fan, Program of Innovative Cancer Therapeutic, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital of Zhejiang University of College of Medicine, 79 Qingchun Road, Hangzhou 310003, China. E-mail: fanw@ 123456zju.edu.cn
          [*]

          Equal contributors.

          Article
          PMC6079154 PMC6079154 6079154
          6079154
          30094089
          c691d567-9f2f-4264-83c5-26926822ab21
          AJCR Copyright © 2018
          History
          : 16 May 2018
          : 01 June 2018
          Categories
          Review Article

          MicroRNA (miRNA),cancer stem cell (CSC),liver cancer,EMT,chemo-resistance

          Comments

          Comment on this article